Document Detail


Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
MedLine Citation:
PMID:  23159210     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Although tolvaptan is a recently approved drug for heart failure and causes aquaresis without affecting renal function, its clinical efficacy for patients with acute decompensated heart failure (ADHF) is yet to be elucidated. METHODS AND RESULTS: We conducted a prospective observational study in patients with ADHF and high risk for worsening renal function (WRF). Risk stratification for WRF was done by scoring system. Of 174 patients, 114 patients were included as high-risk population for WRF. Incidence of WRF, urine output within 24h and 48h, and changes in brain natriuretic peptide (BNP) were recorded in 44 patients treated with tolvaptan plus conventional therapy, and 70 patients with only conventional therapy. Urine output at 24h and 48h after admission were both significantly higher in the tolvaptan group (p=0.001 and <0.001, respectively), and changes in BNP were not significantly different (p=0.351). However, the incidence of WRF was significantly lower in the tolvaptan group compared to the conventional group (22.7% vs 41.4%, p=0.045). Logistic regression analysis showed that treatment with tolvaptan was an independent factor for reducing WRF (hazard ratio 0.28, 95% confidence interval; 0.10-0.84; p=0.023). CONCLUSION: In patients with ADHF with high risk of WRF, treatment with tolvaptan could prevent WRF compared to conventional therapy.
Authors:
Yuya Matsue; Makoto Suzuki; Mie Seya; Ryota Iwatsuka; Akira Mizukami; Wataru Nagahori; Masakazu Ohno; Akihiko Matsumura; Yuji Hashimoto
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-15
Journal Detail:
Title:  Journal of cardiology     Volume:  -     ISSN:  1876-4738     ISO Abbreviation:  J Cardiol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804703     Medline TA:  J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
Affiliation:
Department of Cardiology, Kameda Medical Center, 929 Higashi-chou, Kamogawa-City, Chiba 296-8602, Japan. Electronic address: yuya8950@gmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reference interval of pregnancy-associated plasma protein-A in healthy men and non-pregnant women.
Next Document:  Prediction of atrial fibrillation after ischemic stroke using P-wave signal averaged electrocardiogr...